[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100597084":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":19,"responsibleParty":36,"collaborators":7,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":42,"acronym":7,"eligibilityCriteria":43,"healthyVolunteers":40,"sex":44,"minAge":45,"maxAge":7,"enrollmentInfo":46,"targetDuration":7,"studyType":49,"phases":7,"briefSummary":50,"conditions":51,"keywords":7,"overallStatus":22,"whyStopped":7,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":62},{"fullName":5,"class":6},"Otsuka Pharmaceutical Co., Ltd.","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DRUG","Voclosporin (LUPKYNIS)","In general, for adults, voclosporin should be administered orally at a dose of 23.7 mg BID. The dosage may be appropriately reduced depending on the patient's condition. In principle, at the start of treatment with voclosporin, it should be used in combination with corticosteroids and mycophenolate mofetil.",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Pharmacovigilance Department Otsuka Pharmaceutical Co., Ltd","CONTACT","+81-6-6943-7722","komaniwa.satoshi@otsuka.jp",[20],{"facility":21,"status":22,"city":23,"state":23,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"Pharmacovigilance Department","RECRUITING","Osaka","540-0021","Japan","JP",{"type":28,"coordinates":29},"Point",[30,31],135.50107,34.69379,{"lat":31,"lon":30},[34],{"name":35,"role":16,"phone":17,"phoneExt":7,"email":18},"Study Director",{"type":37,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100597084","lupkynis-drug-use-results-survey-100597084",false,"NCT07053891","LUPKYNIS Drug-use Results Survey","Inclusion Criteria:\n\n* Patients who are newly starting administration of LUPKYNIS for lupus nephritis\n\nExclusion Criteria:\n\n\\-","ALL","15 Years",{"count":47,"type":48},400,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to survey the safety of LUPKYNIS in patients with lupus nephritis under actual use conditions. In addition, information on efficacy will be collected.",[52],"Lupus Nephritis","2025-09-18",{"date":55,"type":56},"2025-09-19","ACTUAL",{"date":58,"type":56},"2025-09-17",{"date":60,"type":48},"2032-06-30",{"name":5,"class":6},1]